Seminars in Oncology
Volume 30, Issue 2 , Pages 136-141, April 2003

Origins of the malignant clone in typical Waldenstrom's macroglobulinemia☆☆

Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals, Southampton UK; and Cattedra e U.O. di Ematologia, Ospedale “A. Sclavo”, Universita di Siena, Italy

Abstract 

Histopathology and phenotypic considerations in IgM-secreting B-cell tumors allow distinction between different diseases, but insight into pathogenesis is restricted. Here, variable region (V) gene analysis can complement classification but, more importantly, can also reveal disease origins and clonal history. We used VH gene analysis to probe origins in Waldenstrom's macroglobulinemia (WM), and contrasted these with the less malignant counterpart, IgM-secreting monoclonal gammopathy of undetermined significance (MGUS). Limited data on WM sequences had previously shown evidence for somatic mutation, but with conflicting analysis of intraclonal variation in tumor sequences. To further the investigation, we analyzed seven cases of WM and compared these with three cases of IgM MGUS. In both diseases, VH genes were somatically mutated with no evidence of intraclonal variation, even at the MGUS stage. A sensitive VH gene-probe assay revealed no evidence for isotype switch transcripts in any of the WM and IgM MGUS cases. These findings reveal an origin of WM and IgM MGUS from a IgM cell, which transforms after cessation of somatic mutation but without initiating switch events. In contrast, IgM-secreting multiple myeloma arises at a later stage in differentiation, when isotype switch mechanisms have been engaged. Semin Oncol 30:136-141. © 2003 Elsevier Inc. All rights reserved.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by The Smokler Fellowship Award from Research Fund for Waldenstroms, Ltd, New York, NY, The Leukaemia Research Fund UK, and Tenovus UK.

☆☆ Address reprint requests to Surinder S. Sahota, PhD, Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals, Tremona Road, Southampton SO16 6YD, UK.

 0093-7754/03/3002-0038$30.00/0

PII: S0093-7754(03)70064-5

doi:10.1053/sonc.2003.50072

Seminars in Oncology
Volume 30, Issue 2 , Pages 136-141, April 2003